Results 11 to 20 of about 26,895 (263)

Peripheral combination treatment of leptin and an SGLT2 inhibitor improved glucose metabolism in insulin-dependent diabetes mellitus mice

Journal of Pharmacological Sciences, 2021
We investigated whether peripheral combination treatment of a sodium–glucose cotransporter 2 (SGLT2) inhibitor and leptin improves glucose metabolism in insulin-dependent diabetes mellitus (IDDM) model mice.
Hiroshi Yaginuma, Ryoichi Banno
exaly   +3 more sources

Effect of a SGLT2 inhibitor on the systemic and intrarenal renin–angiotensin system in subtotally nephrectomized rats

Journal of Pharmacological Sciences, 2018
We aimed to examine the effects of a sodium glucose co-transporter 2 (SGLT2) inhibitor on systemic and intrarenal renin–angiotensin system (RAS) in subtotally nephrectomized non-diabetic rats, a model of chronic kidney disease (CKD).
Takashi Morikawa, Yifan Zhang, Hideki Kobara   +2 more
exaly   +3 more sources

SGLT2 Inhibitors and Their Antiarrhythmic Properties [PDF]

International Journal of Molecular Sciences, 2022
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are gaining ground as standard therapy for heart failure with a class-I recommendation in the recently updated heart failure guidelines from the European Society of Cardiology. Different gliflozins have shown impressive beneficial effects in patients with and without diabetes mellitus type 2, especially
Ewald Kolesnik, Daniel Scherr, Ursula Rohrer, Martin Benedikt, Martin Manninger, Harald Sourij, Dirk von Lewinski   +6 more
openaire   +2 more sources

Sodium-glucose co-transporter-2 inhibitors reduce the risk of new-onset stroke in patients with type 2 diabetes: A population-based cohort study

Frontiers in Cardiovascular Medicine, 2022
BackgroundEpidemiological evidence suggests the association of diabetes with an increased risk of stroke. Clinical studies have investigated the effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on new-onset stroke (NOS), but the results are ...
Tsung-Kun Lin, Tsung-Kun Lin, Yong-Hsin Chen, Yong-Hsin Chen, Jing-Yang Huang, Jing-Yang Huang, Pei-Lun Liao, Mei-Chun Chen, Lung-Fa Pan, Lung-Fa Pan, Gwo-Ping Jong   +10 more
doaj   +1 more source

The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: A nationwide population-based longitudinal cohort study

Diabetes & Vascular Disease Research, 2022
Background The association of the use of sodium-glucose cotransporter 2 (SGLT2) inhibitor and incident dementia remains unclear. This study aimed to evaluate the risk of incident dementia with the use of SGLT2 inhibitor.
Wun-Zhih Siao, Tsung-Kun Lin, Jing-Yang Huang, Chin-Feng Tsai, Gwo-Ping Jong   +4 more
doaj   +1 more source

165 Rates of SGLT2 Inhibitor Use in Patients With Diabetes and Heart Failure in the Southeastern United States

Journal of Clinical and Translational Science, 2022
OBJECTIVES/GOALS: Clinical trials of SGLT2 inhibitors in patients with heart failure (HF) have confirmed a reduction in hospitalization and death. Adoption of novel therapeutics has been slower in Black and female patients. We investigated utilization of
Apoorva Gangavelli, Zihao Liu, Jeffrey Wang, Alexis Okoh, Shivani Patel, Alanna A. Morris   +5 more
doaj   +1 more source

Clinical Outcomes of Diabetic Ketoacidosis in Type 2 Diabetes Patients with and without SGLT2 Inhibitor Treatment: A Retrospective Study

Biomedicines, 2023
Aim: This study aimed to compare the clinical course and outcomes of DKA in T2DM patients who received treatment with SGLT2 inhibitors versus those who did not.
Afif Nakhleh, Areen Othman, Amin Masri, Moshe Zloczower, Sagit Zolotov, Naim Shehadeh   +5 more
doaj   +1 more source

Sodium-Glucose Cotransporter-2 Inhibitor for Renal Function Preservation in Patients with Type 2 Diabetes Mellitus: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement [PDF]

Diabetes & Metabolism Journal, 2020
Diabetes is a leading cause of end-stage renal disease. Therefore, prevention of renal dysfunction is an important treatment goal in the management of diabetes.
Tae Jung Oh, Ju-Young Moon, Kyu Yeon Hur, Seung Hyun Ko, Hyun Jung Kim, Taehee Kim, Dong Won Lee, Min Kyong Moon, ,   +9 more
doaj   +2 more sources

Sodium-glucose co-transporter 2 inhibitor use in patients with diabetes mellitus undergoing endovascular therapy for symptomatic peripheral artery disease

Cardiovascular Diabetology, 2023
Background This study aimed to reveal the prevalence of sodium-glucose co-transporter 2 (SGLT2) inhibitor treatment and its association with restenosis risk in patients with diabetes mellitus undergoing endovascular therapy for symptomatic peripheral ...
Mitsuyoshi Takahara, Yoshimitsu Soga, Masahiko Fujihara, Osamu Iida, Daizo Kawasaki   +4 more
doaj   +1 more source

Renoprotective effect of chronic treatment with sodium-glucose cotransporter 2 inhibitors and its associated factors in Japanese patients with chronic heart failure and diabetes

International Journal of Cardiology: Heart & Vasculature, 2022
Background: Recent clinical trials have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors have beneficial effects on renal function in heart failure patients. This study confirmed the renoprotective effect of treatment with SGLT2 inhibitors in
Go Yokouchi, Takeshi Horio, Naoki Matsumoto, Kohei Fukuda, Ryutaro Yoshimura, Ryosuke Fujiwara, Yujiro Matsuoka, Yuya Sakamoto, Yoshio Iwashima, Yoshiyuki Oshiro, Kohei Fujimoto, Noriaki Kasayuki   +11 more
doaj   +1 more source